Author:
Shankar G.,Arkin S.,Cocea L.,Devanarayan V.,Kirshner S.,Kromminga A.,Quarmby V.,Richards S.,Schneider C. K.,Subramanyam M.,Swanson S.,Verthelyi D.,Yim S.
Publisher
Springer Science and Business Media LLC
Reference47 articles.
1. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov. 2002;1(6):457–62. doi: 10.1038/nrd818 .
2. Schnabel CA, Fineberg SE, Kim DD. Immunogenicity of xenopeptide hormone therapies. Peptides. 2006;27(7):1902–10. doi: 10.1016/j.peptides.2006.01.019 .
3. Kuus-Reichel K, Grauer LS, Karavodin LM, Knott C, Krusemeier M, Kay NE. Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies? Clin Diagn Lab Immunol. 1994;1(4):365–72.
4. Koren E, Zuckerman LA, Mire-Sluis AR. Immune responses to therapeutic proteins in humans—clinical significance, assessment and prediction. Curr Pharm Biotechnol. 2002;3(4):349–60.
5. Schellekens H, Casadevall N. Immunogenicity of recombinant human proteins: causes and consequences. J Neurol. 2004;251 Suppl 2:II4–9. doi: 10.1007/s00415-004-1202-9 .
Cited by
252 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献